FindTrial
Sign In

2:16DU/-ml

2 trials

Sponsors

GlaxoSmithKline Biologicals

Conditions

A single dose of Sanofi Pasteur MSD’s unconjugated 23-valent polysaccharide pneumococcal vaccine (Pneumovax™23) to healthy children who were previously primed with the full three doses of GSK Biologicals’ 10-valent conjugate pneumococcal vaccine or Prevenar™ in the primary vaccination study 10PN-PD-DIT-003. Children will be 11-14 months old at the time of enrolment in this study and will receive concomitantly their booster dose of Infanrix™hexa according to national recommendations.Three dose primary vaccination of preterm infants between 8-16 weeks (56-118 days) of age at the time of first vaccination against Streptococcus pneumoniae.

Phase 3

A phase IIIb open study to assess the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals´ 10-valent pneumococcal conjugate vaccine when co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine in preterm infants as a 3-dose primary immunisation course during the first 6 months of life - 10PN-PD-DIT-015
Active, not recruitingEUCTR2006-002898-47-GR
GlaxoSmithKline BiologicalsThree dose primary vaccination of preterm infants between 8-16 weeks (56-118 days) of age at the time of first vaccination against Streptococcus pneumoniae.
Start: 2007-01-16Target: 300Updated: 2022-08-08

Unknown Phase

A phase IIIa, open, multicentre study to evaluate the immunological memory induced in healthy children following a 3-dose primary vaccination with either GSK Biologicals’ 10-valent pneumococcal conjugate vaccine or PrevenarTM in study 10PN-PD-DIT-003 (105554), via the administration of a single booster dose of a 23-valent pneumococcal plain polysaccharide vaccine. - 10PN-PD-DIT-008
Active, not recruitingEUCTR2006-000560-93-DE
GlaxoSmithKline BiologicalsA single dose of Sanofi Pasteur MSD’s unconjugated 23-valent polysaccharide pneumococcal vaccine (Pneumovax™23) to healthy children who were previously primed with the full three doses of GSK Biologicals’ 10-valent conjugate pneumococcal vaccine or Prevenar™ in the primary vaccination study 10PN-PD-DIT-003. Children will be 11-14 months old at the time of enrolment in this study and will receive concomitantly their booster dose of Infanrix™hexa according to national recommendations.
Start: 2006-06-27Target: 120Updated: 2013-02-11